Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Ed’s stories explore prescription drug ...
FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new results from ...
Independent Newspaper Nigeria on MSN
Nigeria pushes towards zero HIV transmission goal, holds nationwide training on lenacapavir rollout
LAGOS Nigerians living with HIV who achieve virological suppression can expect to live for 33 years without transmitting the virus, according to health experts, as nationwide training begins for the ...
Delivering his budget vote in Parliament on Wednesday, Motsoaledi said stocks will be delivered to 360 health facilities in ...
Please provide your email address to receive an email when new articles are posted on . Twice-yearly lenacapavir injections reduced HIV infections by 96% in a phase 3 trial. Gilead Sciences will begin ...
The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...
The Department of Health in South Africa is set to roll out injectable PrEP, a bi-annual HIV prevention medication, in ...
South African Health Minister Aaron Motsoaledi announced that the country will launch its rollout of the twice-yearly HIV ...
A newly approved drug gives almost total protection against getting HIV. The FDA approved lenacapavir last week. Patients need just two injections of it a year to get that protection, but as NPR's ...
A Prescription Drug User Fee Act target date of August 27, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...
The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted. If ...
South Africa has received its first batch of the highly anticipated HIV prevention medicine Lenacapavir, marking a milestone in the country’s fight against HIV. The initial shipment consists of 37,920 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results